SnapShot: The hallmarks of cancer treatment

Area of Science:

• Oncology
• Cancer Therapeutics
• Molecular Biology

Background:

• Cancer therapy has evolved significantly, moving from traditional cytotoxic chemotherapy to more precise targeted and immune-based treatments.
• Early cytotoxic drugs, while effective, are associated with significant toxicity.
• Molecular profiling guides modern cancer treatments, but challenges like drug resistance persist.

Purpose of the Study:

• To review the evolution of cancer therapeutics.
• To highlight the limitations of current targeted and immune treatments.
• To emphasize the need for strategies that overcome treatment resistance.

Main Methods:

• Literature review of cancer therapy evolution.
• Analysis of cytotoxic, targeted, and immune treatment modalities.
• Discussion of resistance mechanisms and future directions.

Main Results:

• Cytotoxic chemotherapy, though toxic, remains a cornerstone.
• Targeted therapies and immune checkpoint inhibitors show promise but face resistance.
• Engineered modalities like Antibody-Drug Conjugates (ADCs), Bispecific T-cell Engagers (BiTEs), and Chimeric Antigen Receptor T-cell (CAR-T) therapies offer new avenues but have toxicity and antigen loss limitations.

Conclusions:

• Current cancer treatments, including targeted and immune therapies, are limited by toxicity and the emergence of resistance.
• Future cancer treatment combinations must proactively target the evolution of resistance to improve patient outcomes.